Axonics, Inc. (AXNX) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Devices 산업에서 운영. 본사 소재지는 Irvine, CA, 미국. 현재 CEO는 Raymond W. Cohen.
AXNX 을(를) 보유 IPO 날짜 2018-10-31, 797 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.63B.
Axonics, Inc. is a medical technology company that develops and commercializes sacral neuromodulation (SNM) systems to treat bladder and bowel dysfunction disorders, including overactive bladder, urinary incontinence, and fecal incontinence. The company's proprietary rechargeable SNM system delivers mild electrical pulses to the sacral nerve to restore normal communication between the bladder, bowel, and brain. In addition to its SNM platform, Axonics offers Bulkamid, a urethral bulking agent for treating female stress urinary incontinence. The company markets its products through a direct sales force and distributor network across the United States, United Kingdom, Germany, the Netherlands, Nordic countries, and other international markets.
